human
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Sarcomatoid features can arise in renal cell carcinoma of any subtype and are associated with a poor prognosis . Doxorubicin and gemcitabine in a limited series showed activity in aggressive renal tumors and we wished to formally assess the combination in patients with renal cell carcinoma specifically containing sarcomatoid features . The Eastern Cooperative Oncology Group ( ECOG ) conducted a phase II trial of doxorubicin 50 mg/m2 IV push and gemcitabine 1,500 mg/m2 IV over 30 min every 2 weeks in 39 patients with locally advanced or metastatic renal cell carcinoma with sarcomatoid features . Ten patients ( 26 % ) had grade 3 toxicity , and four patients ( 11 % ) had grade 4 toxicities . Although most toxicity was from myelosuppression , one patient died on study from cardiac dysfunction after a cumulative dose of 450 mg/m2 doxorubicin . Six ( 16 % ) patients experienced responses ( 5 partial responses and 1 complete response ) , and ten ( 26 % ) patients had stable disease . In addition , another patient had an unconfirmed partial response and an additional patient experienced over 50 % decrease in her tumor burden after an initial progression . The median overall survival was 8.8 months , and the median progression-free survival was 3.5 months . We conclude that the combination of doxorubicin and gemcitabine , inactive in patients with mostly clear cell histology , demonstrated responses in patients with RCC with sarcomatoid features . We acknowledge the toxicity of this combination but note that limited treatment options exist for this aggressive histology . Only through prospect i ve multicenter trials with comprehensive central pathology review will better treatment options be identified CONTEXT AND OBJECTIVES The European Association of Urology Guideline Group for renal cell carcinoma ( RCC ) has prepared these guidelines to help clinicians assess the current evidence -based management of RCC and to incorporate the present recommendations into daily clinical practice . EVIDENCE ACQUISITION The recommendations provided in the current up date d guidelines are based on a thorough review of available RCC guidelines and review articles combined with a systematic literature search using Medline and the Cochrane Central Register of Controlled Trials . EVIDENCE SYNTHESIS A number of recent prospect i ve r and omised studies concerning RCC are now available with a high level of evidence , whereas earlier publications were based on retrospective analyses , including some larger multicentre validation studies , meta-analyses , and well- design ed controlled studies . CONCLUSIONS These guidelines contain information for the treatment of an individual patient according to a current st and ardised general approach . Up date d recommendations concerning diagnosis , treatment , and follow-up can improve the clinical h and ling of patients with RCC 
    Output:
    
agent
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Sarcomatoid features can arise in renal cell carcinoma of any subtype and are associated with a poor prognosis . Doxorubicin and gemcitabine in a limited series showed activity in aggressive renal tumors and we wished to formally assess the combination in patients with renal cell carcinoma specifically containing sarcomatoid features . The Eastern Cooperative Oncology Group ( ECOG ) conducted a phase II trial of doxorubicin 50 mg/m2 IV push and gemcitabine 1,500 mg/m2 IV over 30 min every 2 weeks in 39 patients with locally advanced or metastatic renal cell carcinoma with sarcomatoid features . Ten patients ( 26 % ) had grade 3 toxicity , and four patients ( 11 % ) had grade 4 toxicities . Although most toxicity was from myelosuppression , one patient died on study from cardiac dysfunction after a cumulative dose of 450 mg/m2 doxorubicin . Six ( 16 % ) patients experienced responses ( 5 partial responses and 1 complete response ) , and ten ( 26 % ) patients had stable disease . In addition , another patient had an unconfirmed partial response and an additional patient experienced over 50 % decrease in her tumor burden after an initial progression . The median overall survival was 8.8 months , and the median progression-free survival was 3.5 months . We conclude that the combination of doxorubicin and gemcitabine , inactive in patients with mostly clear cell histology , demonstrated responses in patients with RCC with sarcomatoid features . We acknowledge the toxicity of this combination but note that limited treatment options exist for this aggressive histology . Only through prospect i ve multicenter trials with comprehensive central pathology review will better treatment options be identified CONTEXT AND OBJECTIVES The European Association of Urology Guideline Group for renal cell carcinoma ( RCC ) has prepared these guidelines to help clinicians assess the current evidence -based management of RCC and to incorporate the present recommendations into daily clinical practice . EVIDENCE ACQUISITION The recommendations provided in the current up date d guidelines are based on a thorough review of available RCC guidelines and review articles combined with a systematic literature search using Medline and the Cochrane Central Register of Controlled Trials . EVIDENCE SYNTHESIS A number of recent prospect i ve r and omised studies concerning RCC are now available with a high level of evidence , whereas earlier publications were based on retrospective analyses , including some larger multicentre validation studies , meta-analyses , and well- design ed controlled studies . CONCLUSIONS These guidelines contain information for the treatment of an individual patient according to a current st and ardised general approach . Up date d recommendations concerning diagnosis , treatment , and follow-up can improve the clinical h and ling of patients with RCC 
    Output:
    